Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the study is to evaluate the safety, improvement of clinical symptoms and laboratory parameters of convalescent immune plasma treatment in severe Covid-19 patients with ARDS.
The aim of the study is to evaluate the safety, improvement of clinical symptoms with hypoxemia, metabolic and laboratory parameters of patients with convalescent immune plasma treatment in severe Covid-19 patients followed up in critical care unit.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Convalescent Plasma Therapy Group | Experimental | One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment. |
|
| Non-Plasma Therapy Group | No Intervention | Standart critical care treatment group |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Convalescent Immune Plasma | Other | One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma ferritin level | Acute phase reactant | 7. day |
| Lymphocyte count | Infection markers | 7. day |
| D-Dimer level | Hypercoagulability | 7. day |
| C-Reactive protein level | Infection markers | 7. day |
| Plasma procalcitonin level | Infection markers | 7. day |
| Plasma fibrinogen level | Coagulopathy | 7. day |
| Measure | Description | Time Frame |
|---|---|---|
| Fractional Inspired Oxygen Level | Arterial oxygenation | 7. day |
| Partial Oxygen Saturation level | Arterial oxygenation | 7. day |
Not provided
Inclusion Criteria Clinical diagnosis of Covid-19
Exclusion Criteria Age lower than 18 Lower plasma IgA levels PaO2/FiO2 higher than 300 mmHg SpO2 higher than 90
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Salih SS Sevdi, Md | Istanbul Bagcılar Training and Research Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Istanbul Bagcılar Training and Research Hospital | Istanbul | 34375 | Turkey (Türkiye) |
Not provided
| ID | Term |
|---|---|
| D012128 | Respiratory Distress Syndrome |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D012120 | Respiration Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Arterial Oxygen level | Arterial oxygenation | 7. day |